Results Recap: Support For Medtronic's 'Suspend Before Low' Insulin Pump Feature; Neuroelectrics' Starstim Treats Epilepsy Seizures
Executive Summary
Medtech Insight's Results Recap covers major device trial results appearing on MedDeviceTracker. This week's edition, covering Feb. 22 through Feb. 28, includes published results from trials of Medtronic’s closed-loop artificial pancreas, Neuroelectrics’ nerve stimulation device to treat seizures, and Myriad’s companion diagnostic for pancreatic cancer.
You may also be interested in...
Medtronic, Capital District Physicians’ Health Plan Partner To 'Gamify' Diabetes Control
Health plan members will be invited to join Medtronic’s Inner Circle patient engagement program, which applies game design to help motivate and encourage patients with diabetes to achieve monthly health-outcome goals.
Myriad Foresees Important Role For Genetic Testing In Pancreatic Cancer, Breast Cancer And Beyond
The results of the POLO trial, showing a benefit of Myriad’s BRACAnalysis CDx companion diagnostic for AstraZeneca’s Lynparza (olaparib) to treat pancreatic cancer offer more support for the new guidelines from the National Comprehensive Cancer Network recommending genetic testing for all pancreatic cancer patients. Myriad also stands to benefit from the growing support for genetic testing of breast cancer patients.
Good News For Senseonics, Medtronic Diabetes Devices
US FDA recently approved the first 90-day CGM system and expanded the labeling for a closed-loop system to treat diabetes.